Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Notice

Government-Owned Inventions; Availability for Licensing

A Notice by the National Institutes of Health on 03/20/2026

• 1.

1.

• Document Details Published Content - Document Details Agencies Department of Health and Human Services National Institutes of Health Document Citation 91 FR 13606 Document Number 2026-05527 Document Type Notice Page 13606
  (1 page) Publication Date 03/20/2026 Published Content - Document Details

• PDF Official Content

  • View printed version (PDF) Official Content

• Document Details Published Content - Document Details Agencies Department of Health and Human Services National Institutes of Health Document Citation 91 FR 13606 Document Number 2026-05527 Document Type Notice Page 13606
  (1 page) Publication Date 03/20/2026 Published Content - Document Details

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • AGENCY:
  • ACTION:
  • SUMMARY:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • Gene Editing for ALPK1 p.Thr237Met Enhanced Content - Table of Contents

• Public Comments Enhanced Content - Public Comments This feature is not available for this document.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data Additional information is not currently available for this document.

Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-05527 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-05527 as it appeared on Public Inspection on
03/19/2026 at 8:45 am.

It was viewed
19
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-05527 (91 FR 13606) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

National Institutes of Health

AGENCY:

National Institutes of Health, HHS.

ACTION:

Notice.

SUMMARY:

The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to this licensing opportunity should be directed to: David Yang at 240-695-6406, or David.Yang@niaid.nih.gov. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION:

Technology description follows:

Gene Editing for ALPK1 p.Thr237Met

Description of Technology: ROSAH syndrome is a rare genetic disease caused by a mutation in the human alpha kinase 1 (ALPK1) gene (p.Thr237Met), leading to vision loss, swollen optic nerves, dry mouth, enlarged spleen, and frequent headaches. Researchers in the Laboratory of Clinical Immunology and Microbiology (LCIM) at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a new approach that can precisely fix the ALPK1 mutation without causing unwanted changes in the patient's DNA. This method uses a base editor combined with a guide RNA to safely and efficiently convert the pathogenic thymine of the mutation back to cytosine. In laboratory tests, this gene editing technology successfully repaired the mutation in patient-derived affected cells with high accuracy and no side effects.

This therapy could be delivered directly to the eye or salivary glands, or patient cells could be corrected outside the body and then returned to the patient, offering hope for personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications:

• Personalized therapy for individuals with disease secondary to the ALPK1 p.Thr237Met genetic variant.
  Competitive Advantages:

• Highly accurate tool that directly repairs the faulty gene that causes ROSAH syndrome, while avoiding unwanted changes elsewhere in DNA.

• Corrects the mutation in most patient cells with few or no mistakes.

• Can be delivered directly to affected areas (e.g., eye or salivary glands) or can treat patient cells outside the body.

• Custom therapy for people with the ALPK1 mutation.

• Effective in cells that don't divide, unlike older gene editing methods.
  Development Stage:

• Pre-Clinical.
  Inventors: Dr. Christina Torres Kozycki, Dr. Colin L. Sweeney, Dr. Uimook Choi, all of NIAID.

Intellectual Property: HHS Reference No. E-044-2024-0. Provisional Patent Application No. 63/733,836, filed on December 13, 2024, and PCT Patent Application No. PCT/US2025/059432, filed on December 12, 2025.

Licensing Contact: To license this technology, please contact David Yang at 240-695-6406, or David.Yang@niaid.nih.gov, and reference E-044-2024-0.

Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Area of specific interest includes human clinical trials. For collaboration opportunities, please contact David Yang at 240-695-6406, or David.Yang@niaid.nih.gov.

Dated: March 18, 2026.

Surekha Vathyam,

Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2026-05527 Filed 3-19-26; 8:45 am]

BILLING CODE 4140-01-P

Published Document: 2026-05527 (91 FR 13606)